D. Shawcross

Platelet‐leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion

V. Patel, D. Shawcross, S. Støy, 2018, Alimentary pharmacology & therapeutics.

Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease

V. Patel, D. Shawcross, C. Woodhouse, 2018, Alimentary pharmacology & therapeutics.

article : the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease

V. Patel, C. Woodhouse, A. Singanayagam, 2017 .

E/A ratio alone cannot reliably diagnose diastolic dysfunction in the assessment before and after TIPS.

G. Auzinger, R. Abeles, D. Shawcross, 2007, Gut.

Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement

R. Butterworth, M. Morgan, J. Bajaj, 2011, Alimentary pharmacology & therapeutics.

OC-029 Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience

H. Preedy, R. Aspinall, M. Hudson, 2014, Gut.

Editorial: platelet transfusions in cirrhosis—do the risks outweigh the unclear benefits? Authors’ reply

S. Støy, D. Shawcross, Debbie L. Shawcross, 2018, Alimentary pharmacology & therapeutics.

Editorial: neutrophil dysfunction in patients with cirrhosis – authors' reply

N. Taylor, Y. Ma, D. Shawcross, 2014, Alimentary pharmacology & therapeutics.